Kevin Appareti is Senior Director, Global Medical Science Liaison in the Chief Medical Office at Royal Philips. He leads the Key Opinion Leader Program and Medical Education Program. He works across Philips’ businesses, markets, and research to build strong internal and external relationships with Key Opinion Leaders (KOLs) and influencers. Kevin partners with internal business, market, and research leaders and external KOLs to develop Strategic KOL Engagement Programs to deliver strategic guidance, leverage clinical and scientific knowledge, foster peer-to-peer relationships, and support clinical and marketing evidence development and medical education in support of Philips development of meaningful innovations.

Dr. Petses is the Medical Information Regional Lead for the Americas at Sanofi US. She is responsible for management and implementation of strategic and tactical medical information objectives across several business units. She has directed teams of medical information professionals who have provided support for products across broad therapeutic areas. She has managed the development of digital communication channels and a data mining tool to improve analytics and insights gathering. Prior to joining Sanofi she completed a Drug Information Residency at Schering-Plough. She earned her Bachelor and Doctor of Pharmacy degrees from St. John’s University in New York.

John Kamp is the Executive Director of the Coalition for Healthcare Communication, comprised of medical marketing agencies, medical mass media and medical journals. The CHC believes that truthful communication about medical products and services advances the public health.

Alan counsels clients and represents them at the FDA and in Congress on many of the critical issues that affect the pharmaceutical industry. He is a recognized expert on the Hatch-Waxman Act and lifecycle management, and is co-author of The Legislative History of the Drug Price Competition and Patent Term Restoration Act. Alan also has extensive experience in biological products, including the new biosimilars legislation, in food additive approvals, orphan drugs, and in over the counter drugs and the procedures used to switch them from prescription to non-prescription status.

In her role, she provides counsel regarding various issues including healthcare regulation, FDA advertising and promotion laws, Lanham Act. Jamie provides legal support to the company on general antitrust matters and is a core participant in several industry groups including PhRMA and the MIWG. Jamie also serves on the Lilly Diabetes executive team and the General Counsel’s staff. Prior to her current role, Jamie served as Assistant Secretary and Corporate Securities Counsel for Lilly, where she worked with the Eli Lilly executive committee and board of directors. Before coming to Lilly, Jamie was an associate at Sidley Austin LLP in Chicago, IL. She is a graduate of DePaul University College of Law, and Purdue University.